Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1,2-naphthoquinone + NADPH + H+
? + NADP+
-
-
-
?
1,4-naphthoquinone + NADPH + H+
? + NADP+
-
-
-
?
13-deoxydoxorubicin + NADPH + H+
?
an anthracyclin, formation of a 13-hydroxy-anthracyclin
-
-
?
2,3-butanedione + NADPH
? + NADP+
-
-
-
?
2,3-butanedione + NADPH + H+
?
-
-
-
?
2,3-hexanedione + NADPH + H+
? + NADP+
-
-
-
?
2-hydroxy-3-butanone + NADPH
2,3-dihydroxybutanol + NADP+
-
-
-
?
3-glutathionyl-4-hydroxynonanal + NADP+
3-glutathionyl nonanoic-delta-lactone + NADPH + H+
-
oxidation of the hemiacetal form of 3-glutathionyl-4-hydroxynonanal, generating the 3-glutathionyl nonanoic-delta-lactone
-
?
3-glutathionyl-4-hydroxynonanal + NADP+
3-glutathionyl-1,4-dihydroxynonane + NADPH + H+
-
-
-
?
3-glutathionyl-4-hydroxynonanal + NADPH + H+
3-glutathionyl-1,4-dihydroxynonane + NADP+
3-glutathionyl-4-hydroxynonanal hemiacetal + NADPH + H+
3-glutathionyl-gamma-nonanolactone + NADP+
-
-
-
?
3-glutathionyl-hexanal + NADPH + H+
3-glutathionyl-hexan-1-ol + NADP+
-
-
-
?
3-glutathionyl-nonanal + NADPH + H+
3-glutathionyl-nonan-1-ol + NADP+
-
-
-
?
3-glutathionyl-propanal + NADPH + H+
3-glutathionyl-propan-1-ol + NADP+
-
-
-
?
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone + NADPH + H+
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol + NADP+
-
-
-
?
4-benzoylpyridine + NADPH + H+
(S)-phenyl(pyridin-4-yl)methanol + NADP+
-
-
-
?
4-benzoylpyridine + NADPH + H+
? + NADP+
-
-
-
?
4-hydroxy-2-hexenal + NADPH + H+
?
-
-
-
?
4-nitrobenzaldehyde + NADPH + H+
4-nitrobenzylalcohol + NADP+
-
-
-
?
6-(4-acetyl-5-fluoropyridin-3-yl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide + NADPH + H+
6-[5-fluoro-4-[(1R)-1-hydroxyethyl]pyridin-3-yl]-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide + NADP+
selective substrate of human carbonyl reductase 1
-
-
?
9,10-phenanthrenequinone + NADPH
? + NADP+
-
-
-
?
9,10-phenanthrenequinone + NADPH + H+
? + NADP+
9,10-phenantrenequinone + NADPH + H+
?
-
-
-
?
cortisol + NADPH + H+
20beta-dihydrocortisol + NADP+
-
-
-
?
daunorubicin + NADPH
daunorubicinol + NADP+
-
-
-
?
daunorubicin + NADPH + H+
daunorubicinol + NADP+
doxorubicin + NADPH
doxorubicinol + NADP+
-
-
-
?
doxorubicin + NADPH + H+
doxorubicinol + NADP+
ethyl acetoacetate + NADPH
? + NADP+
-
-
-
?
glutathionyl-nonanal + NADPH + H+
?
-
-
-
?
isatin + NADPH
? + NADP+
-
-
-
?
isatin + NADPH + H+
3-hydroxy-2-oxoindole + NADP+
-
-
-
?
isatin + NADPH + H+
? + NADP+
-
-
-
?
menadione + NADPH
? + NADP+
-
-
-
?
menadione + NADPH + H+
? + NADP+
mitroxantrone + NADPH + H+
?
naphthazarin + NADPH + H+
?
oracin + NADPH + H+
11-dihydrooracin + NADP+
-
-
-
?
prostaglandin E2 + NADPH + H+
prostaglandin F2alpha + NADP+
-
-
-
?
S-nitrosoglutathione + NADPH + H+
? + NADP+
-
-
-
?
2 ferricyanide + NADPH
2 ferrocyanide + NADP+ + H+
-
-
-
-
?
2,3-bornanedione + NADPH
?
-
-
-
-
?
2,3-butanedione + NADPH
?
-
-
-
-
?
2-nitrobenzaldehyde + NADPH
2-nitrobenzyl alcohol + NADP+
-
-
-
-
?
3-glutathionyl-4-hydroxynonanal + NADPH + H+
3-glutathionyl-1,4-dihydroxynonane + NADP+
-
-
-
-
?
4-benzoylpyridine + NADPH
?
-
-
-
-
?
4-benzoylpyridine + NADPH + H+
(S)-alpha-phenyl-4-pyridylmethanol + NADP+
4-carboxybenzaldehyde + NADPH
4-carboxybenzyl alcohol + NADP+
-
-
-
-
?
4-methylnitrosamino-1-(3-pyridyl)-1-butanone + NADPH + H+
4-methylnitrosamino-1-(3-pyridyl)-1-butanol + NADP+
-
i.e. NNK, genotoxic compound from tobacco smoke, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184
-
-
r
4-nitroacetophenone + NADPH
?
-
-
-
-
?
4-nitrobenzaldehyde + NADPH
4-nitrobenzyl alcohol + NADP+
4-oxo-2-nonenal + NADPH + H+
? + NADP+
-
9% of the activity with 9,10-phenanthrenequinone
-
-
?
4-oxonon-2-enal + NADPH + H+
1-hydroxynon-2-en-4-one + NADP+
4-oxonon-2-enal + NADPH + H+
4-hydroxynon-2-enal + NADP+
4-oxonon-2-enal + NADPH + H+
4-oxononanal + 4-hydroxynon-2-enal + 1-hydroxynon-2-en-4-one + NADP+
-
molecular modeling of substrate binding in the active site
product identification, 4-hydroxynon-2-enal is the major product
-
?
4-oxonon-2-enal + NADPH + H+
4-oxononanal + NADP+
5alpha-androstan-17beta-ol-3-one + NADPH
?
-
-
-
-
?
5alpha-androstane-17beta-ol-3-one + NADPH
? + NADP+
-
-
-
-
?
5alpha-androstane-3,17-dione + NADPH
?
-
only enzyme forms CR2, CR8
-
-
?
5alpha-androstane-3,17-dione + NADPH
? + NADP+
-
-
-
-
?
5beta-androstan-17beta-ol-3-one + NADPH
?
-
only enzyme forms CR2, CR8
-
-
?
5beta-pregnan-3alpha-ol-20-one + NADPH
? + NADP+
-
-
-
-
?
9,10-phenanthrenequinone + NADPH
?
-
-
-
-
?
9,10-phenanthrenequinone + NADPH
? + NADP+
-
-
-
?
9,10-phenanthrenequinone + NADPH + H+
? + NADP+
alpha-tocopherolquinone + NADPH
?
-
-
-
-
?
benzoylpyridine + NADPH + H+
?
-
-
-
-
r
bupropion + NADPH + H+
erythrohydrobupropion + NADP+
-
-
in liver cytosol, antidepressant bupropion is reduced to erythrohydrobupropion and threohydrobupropion
-
?
bupropion + NADPH + H+
threohydrobupropion + NADP+
-
-
in liver cytosol, antidepressant bupropion is reduced to erythrohydrobupropion and threohydrobupropion
-
?
daunorubicin + NADPH
?
-
-
-
-
?
daunorubicin + NADPH
daunorubicinol + NADP+
-
-
-
-
?
duroquinone + NADPH
?
-
-
-
-
?
glutathione-4-oxonon-2-enal + NADPH + H+
glutathione-4-hydroxynon-2-enal + NADP+
glutathione-4-oxononanal + NADPH + H+
glutathione-4-hydroxynonanal + NADP+
-
conjugate, molecular modeling of substrate binding in the active site
-
-
?
hydrindantin + NADPH
?
-
-
-
-
?
indole 3-acetaldehyde + NADPH
indole-3-ol + NADP+
-
-
-
-
?
isatin + NADPH
? + NADP+
-
-
-
?
isatin + NADPH + H+
3-hydroxy-2-oxoindole + NADP+
-
-
-
-
?
menadione + NADPH
? + NADP+
menadione + NADPH + H+
?
-
-
-
-
?
menadione + NADPH + H+
? + NADP+
-
48% of the activity with 9,10-phenanthrenequinone
-
-
?
methylglyoxal + NADPH
?
-
-
-
-
?
NADPH + H+ + oxidized 2,6-dichlorophenolindophenol
NADP+ + reduced 2,6-dichlorophenolindophenol
-
-
-
-
?
oracin + NADPH + H+
dihydrooracin + NADP+
phenylglyoxal + NADPH
?
-
-
-
-
?
prostaglandin A1-GSH + NADPH
?
-
-
-
-
?
prostaglandin B2 + NADPH
?
-
-
-
-
?
prostaglandin E1 + NADPH + H+
?
-
-
-
-
r
prostaglandin E2 + NADPH
?
prostaglandin E2 + NADPH
prostaglandin F2alpha + NADP+
-
-
-
-
?
pyridine-4-carboxaldehyde + NADPH
?
-
-
-
-
?
S-nitrosoglutathione + NADPH + H+
? + NADP+
no substrate for wild-type, but substrate for mutants D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244P, P230W/D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244P, and Q142M/C143S/P230W/D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244P/H270S
-
-
?
ubiquinone-1 + NADPH
?
-
-
-
-
?
additional information
?
-
3-glutathionyl-4-hydroxynonanal + NADPH + H+
3-glutathionyl-1,4-dihydroxynonane + NADP+
-
-
-
?
3-glutathionyl-4-hydroxynonanal + NADPH + H+
3-glutathionyl-1,4-dihydroxynonane + NADP+
-
-
-
-
?
9,10-phenanthrenequinone + NADPH + H+
? + NADP+
-
-
-
?
9,10-phenanthrenequinone + NADPH + H+
? + NADP+
-
-
-
?
9,10-phenanthrenequinone + NADPH + H+
? + NADP+
-
-
-
?
daunorubicin + NADPH + H+
daunorubicinol + NADP+
-
-
-
?
daunorubicin + NADPH + H+
daunorubicinol + NADP+
-
-
-
-
?
daunorubicin + NADPH + H+
daunorubicinol + NADP+
-
-
-
?
daunorubicin + NADPH + H+
daunorubicinol + NADP+
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
daunorubicin + NADPH + H+
daunorubicinol + NADP+
an anthracyclin, formation of a 13-hydroxy-anthracyclin
-
-
?
doxorubicin + NADPH + H+
doxorubicinol + NADP+
-
-
-
?
doxorubicin + NADPH + H+
doxorubicinol + NADP+
-
-
-
-
?
doxorubicin + NADPH + H+
doxorubicinol + NADP+
-
-
-
?
doxorubicin + NADPH + H+
doxorubicinol + NADP+
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
doxorubicin + NADPH + H+
doxorubicinol + NADP+
an anthracyclin, formation of a 13-hydroxy-anthracyclin
-
-
?
doxorubicin + NADPH + H+
doxorubicinol + NADP+
CBR1 is a predominant hepatic doxorubicin reductase
-
-
?
menadione + NADPH + H+
?
-
-
-
?
menadione + NADPH + H+
?
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
menadione + NADPH + H+
?
an anthracyclin, formation of a 13-hydroxy-anthracyclin
-
-
?
menadione + NADPH + H+
? + NADP+
-
-
-
?
menadione + NADPH + H+
? + NADP+
-
-
-
-
?
menadione + NADPH + H+
? + NADP+
-
-
-
?
menadione + NADPH + H+
? + NADP+
-
-
-
-
?
mitroxantrone + NADPH + H+
?
-
-
-
?
mitroxantrone + NADPH + H+
?
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
mitroxantrone + NADPH + H+
?
an anthracyclin, formation of a 13-hydroxy-anthracyclin
-
-
?
naphthazarin + NADPH + H+
?
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
naphthazarin + NADPH + H+
?
an anthracyclin, formation of a 13-hydroxy-anthracyclin
-
-
?
4-benzoylpyridine + NADPH + H+
(S)-alpha-phenyl-4-pyridylmethanol + NADP+
-
-
-
-
?
4-benzoylpyridine + NADPH + H+
(S)-alpha-phenyl-4-pyridylmethanol + NADP+
-
-
-
?
4-nitrobenzaldehyde + NADPH
4-nitrobenzyl alcohol + NADP+
-
-
-
-
?
4-nitrobenzaldehyde + NADPH
4-nitrobenzyl alcohol + NADP+
-
-
-
?
4-oxonon-2-enal + NADPH + H+
1-hydroxynon-2-en-4-one + NADP+
-
-
-
-
?
4-oxonon-2-enal + NADPH + H+
1-hydroxynon-2-en-4-one + NADP+
-
metabolic inactivation of the lipid peroxidation product, pathway overview
-
-
?
4-oxonon-2-enal + NADPH + H+
4-hydroxynon-2-enal + NADP+
-
-
-
-
?
4-oxonon-2-enal + NADPH + H+
4-hydroxynon-2-enal + NADP+
-
metabolic inactivation of the lipid peroxidation product, pathway overview
-
-
?
4-oxonon-2-enal + NADPH + H+
4-oxononanal + NADP+
-
-
-
-
?
4-oxonon-2-enal + NADPH + H+
4-oxononanal + NADP+
-
metabolic inactivation of the lipid peroxidation product, pathway overview
-
-
?
9,10-phenanthrenequinone + NADPH + H+
? + NADP+
-
-
-
-
?
9,10-phenanthrenequinone + NADPH + H+
? + NADP+
-
-
-
?
glutathione-4-oxonon-2-enal + NADPH + H+
glutathione-4-hydroxynon-2-enal + NADP+
-
-
-
-
?
glutathione-4-oxonon-2-enal + NADPH + H+
glutathione-4-hydroxynon-2-enal + NADP+
-
metabolic inactivation of the lipid peroxidation product, pathway overview
-
-
?
menadione + NADPH
?
-
-
-
-
?
menadione + NADPH
?
-
best substrate
-
-
?
menadione + NADPH
? + NADP+
-
-
-
-
?
menadione + NADPH
? + NADP+
-
-
-
?
oracin + NADPH + H+
dihydrooracin + NADP+
-
a cytostatic drug, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184, stereochemical ratio of 3:1 for R:S enantiomers of the pro-chiral carbonyl centre of oracin, inactivation of the anti-cancer drug
-
-
r
oracin + NADPH + H+
dihydrooracin + NADP+
-
a cytostatic drug, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184, stereochemical ratio of 3:1 for R:S enantiomers of the pro-chiral carbonyl centre of oracin, inactivation reaction
-
-
r
prostaglandin E2 + NADPH
?
-
-
-
-
?
prostaglandin E2 + NADPH
?
-
only enzyme forms CR2, CR8
-
-
?
additional information
?
-
CBR1 3'-untranslated region polymorphism 1096G-A in DNA samples from whites, and livers with homozygous G/G genotypes show a trend toward higher CBR1 mRNA levels compared with samples with heterozygous G/A genotypes. CBR1 1096G-A genotype status is associated with CBR1 protein levels
-
-
?
additional information
?
-
-
CBR1 3'-untranslated region polymorphism 1096G-A in DNA samples from whites, and livers with homozygous G/G genotypes show a trend toward higher CBR1 mRNA levels compared with samples with heterozygous G/A genotypes. CBR1 1096G-A genotype status is associated with CBR1 protein levels
-
-
?
additional information
?
-
inactive towards menadione
-
-
?
additional information
?
-
inactive towards menadione
-
-
?
additional information
?
-
no doxorubicin or menadione reduction is catalyzed by CBR3
-
-
?
additional information
?
-
-
no doxorubicin or menadione reduction is catalyzed by CBR3
-
-
?
additional information
?
-
single nucleotide polymorphism V88I and P131S mutations exhibit a 20 to 40% decrease in catalytic efficiency (kcat/Km) compared with that for the wild-type enzyme
-
-
?
additional information
?
-
-
single nucleotide polymorphism V88I and P131S mutations exhibit a 20 to 40% decrease in catalytic efficiency (kcat/Km) compared with that for the wild-type enzyme
-
-
?
additional information
?
-
the presence of the glutathionyl moiety in the substrates appears as a necessary requirement for the susceptibility by hCBR1. The corresponding alkanals and alkenals, and the cysteinyl and gamma-glutamyl-cysteinylalkanals adducts are either ineffective or very poorly active as CBR1 substrates
-
-
?
additional information
?
-
-
the presence of the glutathionyl moiety in the substrates appears as a necessary requirement for the susceptibility by hCBR1. The corresponding alkanals and alkenals, and the cysteinyl and gamma-glutamyl-cysteinylalkanals adducts are either ineffective or very poorly active as CBR1 substrates
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
overview
-
-
?
additional information
?
-
-
overview
-
-
?
additional information
?
-
-
no activity with 1-hydroxynon-2-en-4-one and 4-hydroxynon-2-enal
-
-
?
additional information
?
-
-
the enzyme interconvertes 11-oxo-glucocorticoids to their 11-hydroxy metabolites, reaction of EC 1.1.1.146, but is also active as carbonyl reductase, EC 1.1.1.184, in detoxification of xenobiotic carbonyl compounds reducing them to alcohols that are easier to conjugate and eliminate
-
-
?
additional information
?
-
-
the enzyme is responsible for detoxifcation of reactive aldehydes, CR has a potential physiological role for neuroprotection in humans and represents a signifcant pathway for the detoxifcation of reactive aldehydes derived from lipid peroxidation, CR is essential for neuronal cell survival and to confer protection against oxidative stress-induced brain degeneration, overview
-
-
?
additional information
?
-
-
the enzyme metabolizes prostaglandins, steroids, quinines, and anthracycline antibiotics, enzyme expression is inversely associated with tumor progression and angiogenesis
-
-
?
additional information
?
-
-
the enzyme is active with steroids and prostaglandins
-
-
?
additional information
?
-
-
the enzyme shows pluripotent substrate specificity being active as 11beta-hydroxysteroid dehydrogenase, EC 1.1.1.146, and carbonyl reductase, EC 1.1.1.184
-
-
?
additional information
?
-
inactive towards menadione
-
-
?
additional information
?
-
inactive towards menadione
-
-
?
additional information
?
-
-
no activity with 5alpha-androstane-3alpha-ol-17-one
-
-
?
additional information
?
-
-
carbonyl reductase oxidizes the hydroxyl group of 3-glutathionyl-4-hydroxynonanal in its hemiacetal form, with the formation of the corresponding 3-glutathionyl nonanoic-delta-lactone. The enzyme is practically inactive toward trans-4-hydroxy-2-nonenal, buthionine sulfoximine, N-acetylcysteine
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
4-nitrobenzaldehyde + NADPH + H+
4-nitrobenzylalcohol + NADP+
-
-
-
?
cortisol + NADPH + H+
20beta-dihydrocortisol + NADP+
-
-
-
?
daunorubicin + NADPH + H+
daunorubicinol + NADP+
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
doxorubicin + NADPH + H+
doxorubicinol + NADP+
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
menadione + NADPH + H+
?
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
mitroxantrone + NADPH + H+
?
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
naphthazarin + NADPH + H+
?
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties
-
-
?
4-methylnitrosamino-1-(3-pyridyl)-1-butanone + NADPH + H+
4-methylnitrosamino-1-(3-pyridyl)-1-butanol + NADP+
-
i.e. NNK, genotoxic compound from tobacco smoke, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184
-
-
r
4-oxonon-2-enal + NADPH + H+
1-hydroxynon-2-en-4-one + NADP+
-
metabolic inactivation of the lipid peroxidation product, pathway overview
-
-
?
4-oxonon-2-enal + NADPH + H+
4-hydroxynon-2-enal + NADP+
-
metabolic inactivation of the lipid peroxidation product, pathway overview
-
-
?
4-oxonon-2-enal + NADPH + H+
4-oxononanal + NADP+
-
metabolic inactivation of the lipid peroxidation product, pathway overview
-
-
?
glutathione-4-oxonon-2-enal + NADPH + H+
glutathione-4-hydroxynon-2-enal + NADP+
-
metabolic inactivation of the lipid peroxidation product, pathway overview
-
-
?
oracin + NADPH + H+
dihydrooracin + NADP+
-
a cytostatic drug, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184, stereochemical ratio of 3:1 for R:S enantiomers of the pro-chiral carbonyl centre of oracin, inactivation of the anti-cancer drug
-
-
r
additional information
?
-
additional information
?
-
-
the enzyme interconvertes 11-oxo-glucocorticoids to their 11-hydroxy metabolites, reaction of EC 1.1.1.146, but is also active as carbonyl reductase, EC 1.1.1.184, in detoxification of xenobiotic carbonyl compounds reducing them to alcohols that are easier to conjugate and eliminate
-
-
?
additional information
?
-
-
the enzyme is responsible for detoxifcation of reactive aldehydes, CR has a potential physiological role for neuroprotection in humans and represents a signifcant pathway for the detoxifcation of reactive aldehydes derived from lipid peroxidation, CR is essential for neuronal cell survival and to confer protection against oxidative stress-induced brain degeneration, overview
-
-
?
additional information
?
-
-
the enzyme metabolizes prostaglandins, steroids, quinines, and anthracycline antibiotics, enzyme expression is inversely associated with tumor progression and angiogenesis
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2E)-1-(2,4-dihydroxyphenyl)-3-(2',4',6-trihydroxy-5'-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]biphenyl-3-yl)prop-2-en-1-one
-
3',4',7-tris[O-(2-hydroxyethyl)]rutin
-
3-(2-(2,4-dihydroxyphenyl)-1-[hydroxy(4-hydroxyphenyl)methyl]-2-oxoethyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
3-[2,3-dihydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-4H-chromen-4-one
-
3-[2-(2,4-dihydroxyphenyl)-1-(4-hydroxybenzyl)-2-oxoethyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
4-amino-1-tert-butyl-3-(2-hydroxyphenyl)pyrazolo[3,4-d]pyrimidine
-
7-monohydroxyethylrutoside
inhibits the activity of CBR1 V88 and CBR1 I88 in a concentration-dependent manner. It acts as a competitive CBR1 inhibitor when using daunorubicin as a substrate and acts as an uncompetitive CBR1 inhibitor for the small quinone substrate menadione. It inhibits the binding of NADPH in an uncompetitive manner for both substrates
7-O-beta-D-glucopyranos2-ulosyl-quercetin
-
Barbital
18% inhibition at 1 mM
daidzein
71% residual activity at 0.05 mM
daidzin
74% residual activity at 0.05 mM
Disulfiram
43.5% inhibition at 0.1 mM
Ethacrynic acid
34.4% inhibition at 0.1 mM
genistein
63% residual activity at 0.05 mM
menadione
32.6% inhibition at 0.01 mM, 95.7% inhibition at 0.1 mM
14,16-dihydroxy-3,8-dimethyl-3,4,5,6,9,10-hexahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione
-
zearalenone analogue
18beta-glycyrrhetinic acid
-
inhibits the reduction of bupropion in liver microsomes
2,3-Butanedione
-
irreversible inactivation
4-Oxo-4H-benzopyran-2-carboxylic acid
-
-
4-oxonon-2-enal
-
the substrate is also a mechanism-based inhibitor of the enzyme resulting in 50% inactivation of the enzyme-NADPH complex, presence of cofactor is required for inhibition
glycyrrhetinic acid
-
inhibits both 11beta-hydroxysteroid dehydrogenase and carbonyl reductase activities of the enzyme potently
menadione
-
inhibits the reduction of bupropion in liver cytosol
p-hydroxymercuribenzoate
-
-
Phenylglyoxal
-
irreversible inactivation
Tetramethyleneglutaric acid
-
-
additional information
-
no inhibition by NADP+
-
quercetin
-
quercetin
56.4% inhibition at 0.01 mM, 81.6% inhibition at 0.1 mM
quercitrin
-
rutin
-
S-nitrosoglutathione
substrate inhibition above 5 * Km, enzyme is covalantly modified. Treatment with dithiothreitol, but not with ascorbic acid, rescues the activity
S-nitrosoglutathione
treatment leads concentration-dependent S-glutathionylation of cysteines at positions 122, 150, 226, 227. Residues C226/C227 form a disulfide bond. Treatment results in a 25fold decrease in kcat with menadione, 4-benzoylpyridine, 2,3-hexanedione, daunorubicinand 1,4-naphthoquinone, with concomitant increase in kcat for substrates containing a 1,2-diketo group in a ring structure. Except for 9,10-phenanthrenequinone, all changes in kcat are at least in part compensated for by a similar change in Km, overall yielding no drastic changes in catalytic efficiency
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma of Lung
Human carbonyl reductase 1 is an S-nitrosoglutathione reductase.
Brain Injuries
Carbonyl Reductase 1 Attenuates Ischemic Brain Injury by Reducing Oxidative Stress and Neuroinflammation.
Breast Neoplasms
Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Breast Neoplasms
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
Carcinogenesis
Association between CBR1 polymorphisms and NSCLC in the Chinese population.
Carcinoma
Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Carcinoma
Decreased carbonyl reductase 1 expression promotes tumor growth via epithelial mesenchymal transition in uterine cervical squamous cell carcinomas.
Carcinoma
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Carcinoma
Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma.
Carcinoma, Hepatocellular
Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.
Carcinoma, Hepatocellular
Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Carcinoma, Squamous Cell
Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Decreased carbonyl reductase 1 expression promotes tumor growth via epithelial mesenchymal transition in uterine cervical squamous cell carcinomas.
Carcinoma, Squamous Cell
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Cardiotoxicity
Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.
Cardiotoxicity
DNA sequence variants in the carbonyl reductase 1 (cbr1) gene in seven breeds of Canis lupus familiaris.
Cardiotoxicity
EXPRESSION OF THE ANTHRACYCLINE METABOLIZING ENZYME CARBONYL REDUCTASE 1 (CBR1) IN HEARTS FROM DONORS WITH DOWN SYNDROME.
Cardiotoxicity
Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Cardiotoxicity
Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1.
Cardiotoxicity
Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
Cardiotoxicity
Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1.
Cardiotoxicity
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Dehydration
An unusual dehydratase acting on glycerate and a ketoreducatse stereoselectively reducing ?-ketone in polyketide starter unit biosynthesis.
Dehydration
Inhibition of mammalian fatty acid synthetase activity by NADP involves decreased mobility of the 4'-phosphopantetheine prosthetic group.
Dehydration
Reconstitution of a Type II Polyketide Synthase that Catalyzes Polyene Formation.
Dehydration
Stereospecificity of the dehydratase domain of the erythromycin polyketide synthase.
Diabetes Mellitus, Type 2
Genetic variation in the carbonyl reductase 3 gene confers risk of type 2 diabetes and insulin resistance: a potential regulator of adipogenesis.
Down Syndrome
EXPRESSION OF THE ANTHRACYCLINE METABOLIZING ENZYME CARBONYL REDUCTASE 1 (CBR1) IN HEARTS FROM DONORS WITH DOWN SYNDROME.
Drug Resistant Epilepsy
CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies.
Gastrointestinal Neoplasms
Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers.
Heart Failure
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Insulin Resistance
Genetic variation in the carbonyl reductase 3 gene confers risk of type 2 diabetes and insulin resistance: a potential regulator of adipogenesis.
Keloid
Upregulation of the NNP-1 (novel nuclear protein-1, D21S2056E) gene in keloid tissue determined by cDNA microarray and in situ hybridization.
Kidney Failure, Chronic
Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease.
Leiomyosarcoma
Overexpression of carbonyl reductase 1 inhibits malignant behaviors and epithelial mesenchymal transition by suppressing TGF-? signaling in uterine leiomyosarcoma cells.
Leukemia
Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide.
Leukemia
Correction: Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide.
Leukemia, Myeloid, Acute
Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Liver Diseases
Identification and Analysis of the Tegument Protein and Excretory-Secretory Products of the Carcinogenic Liver Fluke Clonorchis sinensis.
Lung Neoplasms
Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells - Involvement of carbonyl reductase 1.
Lung Neoplasms
Induction of carbonyl reductase 1 (CBR1) expression in human lung tissues and lung cancer cells by the cigarette smoke constituent benzo[a]pyrene.
Malformations of Cortical Development
CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies.
Neoplasm Metastasis
Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis.
Neoplasm Metastasis
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Neoplasm Metastasis
Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.
Neoplasms
Antioxidants: friends or foe in prevention or treatment of cancer: the debate of the century.
Neoplasms
Association between CBR1 polymorphisms and NSCLC in the Chinese population.
Neoplasms
Carbonyl Reductase 3 (CBR3) Mediates 9-cis-Retinoic Acid-Induced Cytostatis and is a Potential Prognostic Marker for Oral Malignancy.
Neoplasms
Decreased carbonyl reductase 1 expression promotes tumor growth via epithelial mesenchymal transition in uterine cervical squamous cell carcinomas.
Neoplasms
Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation.
Neoplasms
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Neoplasms
Identification and Analysis of the Tegument Protein and Excretory-Secretory Products of the Carcinogenic Liver Fluke Clonorchis sinensis.
Neoplasms
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Neoplasms
Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling.
Neoplasms
Overexpression of carbonyl reductase 1 inhibits malignant behaviors and epithelial mesenchymal transition by suppressing TGF-? signaling in uterine leiomyosarcoma cells.
Neoplasms
Regulation of Human Carbonyl Reductase 3 (CBR3; SDR21C2) Expression by Nrf2 in Cultured Cancer Cells.
Neoplasms
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
Neuroinflammatory Diseases
Carbonyl Reductase 1 Attenuates Ischemic Brain Injury by Reducing Oxidative Stress and Neuroinflammation.
Obesity
Carbonyl reductase 1 amplifies glucocorticoid action in adipose tissue and impairs glucose tolerance in lean mice.
Obesity
Carbonyl reductase 1 catalyzes 20?-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity.
Ovarian Neoplasms
Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation.
Ovarian Neoplasms
Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models.
Ovarian Neoplasms
Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.
Ovarian Neoplasms
Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling.
Prostatic Neoplasms
Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.
Reperfusion Injury
Upregulation of Carbonyl Reductase 1 by Nrf2 as a Potential Therapeutic Intervention for Ischemia/ Reperfusion Injury during Liver Transplantation.
Squamous Cell Carcinoma of Head and Neck
Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Squamous Cell Carcinoma of Head and Neck
Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma.
Tuberculosis
Crystal structure of FabG4 from Mycobacterium tuberculosis reveals the importance of C-terminal residues in ketoreductase activity.
Tuberculosis
F420H2 Is Required for Phthiocerol Dimycocerosate Synthesis in Mycobacteria.
Tuberous Sclerosis
CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.07 - 0.117
1,2-naphthoquinone
0.0073 - 0.032
1,4-Naphthoquinone
0.06 - 0.159
2,3-Hexanedione
0.0238
3-glutathionyl-hexanal
pH 8.4, 25°C
0.0065
3-glutathionyl-nonanal
pH 8.4, 25°C
0.0207
3-glutathionyl-propanal
pH 8.4, 25°C
5.85 - 7.84
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
0.016 - 0.25
4-benzoylpyridine
0.0128 - 0.0354
9,10-phenanthrenequinone
0.0046
9,10-phenantrenequinone
at pH 8.4 and 37°C
-
0.043 - 0.089
daunorubicin
0.132 - 0.335
doxorubicin
0.0065
glutathionyl-nonanal
at pH 8.4 and 37°C
-
0.0045
NADPH
pH 8.4, 25°C
0.028 - 0.81
S-nitrosoglutathione
0.8
2-nitrobenzaldehyde
-
-
0.033
3-glutathionyl-4-hydroxynonanal
-
pH 8.4, 37°C
0.000000053 - 0.45
4-benzoylpyridine
0.38 - 0.65
4-formylbenzoic acid
-
Km depending on enzyme form
1.3 - 2.5
4-Nitroacetophenone
-
Km depending on enzyme form
0.13 - 2
4-nitrobenzaldehyde
0.345
4-oxonon-2-enal
-
pH 7.4, 37°C, recombinant enzyme
0.05 - 0.1
5alpha-androstan-17beta-ol-3-one
0.15
5alpha-androstane-3,17-dione
-
form CR2
0.0043 - 0.078
9,10-phenanthrenequinone
0.329
glutathione-4-oxonon-2-enal
-
pH 7.4, 37°C, recombinant enzyme
0.000000067 - 0.07
menadione
0.14 - 0.21
Prostaglandin B2
-
Km depending on enzyme form
0.45
prostaglandin E1
-
enzyme form CR8
0.1 - 0.32
prostaglandin E2
0.49 - 2
pyridine-4-carboxaldehyde
0.832 - 2.93
S-nitrosoglutathione
0.015 - 0.017
ubiquinone-1
-
Km depending on enzyme form
additional information
additional information
-
0.07
1,2-naphthoquinone
wild-type, pH 7.4, 25°C
0.07
1,2-naphthoquinone
wild-type, pH 7.4, 37°C
0.117
1,2-naphthoquinone
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.117
1,2-naphthoquinone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.0073
1,4-Naphthoquinone
wild-type, pH 7.4, 25°C
0.0073
1,4-Naphthoquinone
wild-type, pH 7.4, 37°C
0.032
1,4-Naphthoquinone
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.032
1,4-Naphthoquinone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.06
2,3-Hexanedione
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.06
2,3-Hexanedione
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.159
2,3-Hexanedione
wild-type, pH 7.4, 25°C
0.159
2,3-Hexanedione
wild-type, pH 7.4, 37°C
5.85
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
7.84
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
wild-type, pH 7.4, 37°C
0.016
4-benzoylpyridine
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.016
4-benzoylpyridine
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.25
4-benzoylpyridine
wild-type, pH 7.4, 25°C
0.25
4-benzoylpyridine
wild-type, pH 7.4, 37°C
0.0128
9,10-phenanthrenequinone
mutant C227S, pH 7.4, temperature not specified in the publication
0.018
9,10-phenanthrenequinone
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.018
9,10-phenanthrenequinone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.032
9,10-phenanthrenequinone
wild-type, pH 7.4, 25°C
0.032
9,10-phenanthrenequinone
wild-type, pH 7.4, 37°C
0.0354
9,10-phenanthrenequinone
wild-type CBR1
0.0354
9,10-phenanthrenequinone
wild-type, pH 7.4, temperature not specified in the publication
0.043
daunorubicin
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.051
daunorubicin
wild-type
0.051
daunorubicin
single nucleotide polymorphism V88I mutation
0.067
daunorubicin
wild-type, pH 7.4, 37°C
0.0852
daunorubicin
pH 7.4, 37°C
0.089
daunorubicin
single nucleotide polymorphism P131S mutation
0.132
doxorubicin
in stomach
0.134
doxorubicin
in kidney
0.14
doxorubicin
in colon
0.163
doxorubicin
in liver
0.167
doxorubicin
purified enzyme
0.231
doxorubicin
in lung
0.239
doxorubicin
in heart
0.244
doxorubicin
in skeletal muscle
0.287
doxorubicin
wild-type
0.325
doxorubicin
single nucleotide polymorphism P131S mutation
0.335
doxorubicin
single nucleotide polymorphism V88I mutation
0.0008
isatin
wild-type, pH 7.4, 37°C
0.0078
isatin
wild-type CBR1
0.008
isatin
wild-type, pH 7.4, 25°C
0.017
isatin
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.017
isatin
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.014
menadione
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.014
menadione
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.018
menadione
wild-type, pH 7.4, 25°C
0.018
menadione
wild-type, pH 7.4, 37°C
0.018
menadione
single nucleotide polymorphism V88I mutation
0.024
menadione
wild-type
0.045
menadione
single nucleotide polymorphism P131S mutation
0.034
oracin
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.096
oracin
wild-type, pH 7.4, 37°C
0.028
S-nitrosoglutathione
wild-type, pH 7.4, temperature not specified in the publication
0.81
S-nitrosoglutathione
mutant C227S, pH 7.4, temperature not specified in the publication
0.000000053
4-benzoylpyridine
-
wild-type
0.000000058
4-benzoylpyridine
-
mutant P230W
0.3
4-benzoylpyridine
pH 6.5, 25°C
0.31 - 0.45
4-benzoylpyridine
-
Km depending on enzyme form
0.13
4-nitrobenzaldehyde
pH 6.5, 25°C
1.1
4-nitrobenzaldehyde
-
-
1.3 - 1.6
4-nitrobenzaldehyde
-
Km depending on enzyme form
1.6 - 2
4-nitrobenzaldehyde
-
Km depending on enzyme form
0.05
5alpha-androstan-17beta-ol-3-one
-
form CR2
0.1
5alpha-androstan-17beta-ol-3-one
-
-
0.0043
9,10-phenanthrenequinone
residues 142-143, 230, 236-244, 270 of CBR3 exchanged to the corresponding amino acids of CBR1
0.0089
9,10-phenanthrenequinone
residues 230, 236-244, 270 of CBR3 exchanged to the corresponding amino acids of CBR1
0.0092
9,10-phenanthrenequinone
residues 97-98, 230, 236-244 of CBR3 exchanged to the corresponding amino acids of CBR1
0.0393
9,10-phenanthrenequinone
residues 142-143, 230, 236-244 of CBR3 exchanged to the corresponding amino acids of CBR1
0.0564
9,10-phenanthrenequinone
residues 230, 236244 of CBR3 exchanged to the corresponding amino acids of CBR1
0.078
9,10-phenanthrenequinone
wild-type CBR3 and mutant V244M. Residues 236-244, 262-277, 236-244/262-277 or 230 of CBR3 exchanged to the corresponding amino acids of CBR1
0.13
daunorubicin
-
enzyme form CR8
0.14
daunorubicin
-
mutant V88I, 37°C, pH 7.4
0.173
daunorubicin
-
wild-type, 37°C, pH 7.4
0.0225
isatin
residues 142-143, 230, 236-244, 270 of CBR3 exchanged to the corresponding amino acids of CBR1
0.0315
isatin
residues 142-143, 230, 236-244 of CBR3 exchanged to the corresponding amino acids of CBR1
0.0327
isatin
residues 230, 236-244, 270 of CBR3 exchanged to the corresponding amino acids of CBR1
0.0471
isatin
residues 230, 236-244 of CBR3 exchanged to the corresponding amino acids of CBR1
0.055
isatin
residues 97-98, 230, 236-244 of CBR3 exchanged to the corresponding amino acids of CBR1
1.6
isatin
residues 236-244 of CBR3 exchanged to the corresponding amino acids of CBR1
4
isatin
wild-type CBR3 and mutant V244M. Residues 262-277, 236-244/262-277 or 230 of CBR3 exchanged to the corresponding amino acids of CBR1
0.000000067
menadione
-
wild-type
0.000000079
menadione
-
mutant P230W
0.0229
menadione
-
pH 7.4, 37°C, recombinant isozyme CBR M244
0.0246
menadione
-
pH 7.4, 37°C, recombinant isozyme CBR V244
0.025
menadione
-
pH 7.4, 37°C, recombinant enzyme
0.042
menadione
-
wild-type, 37°C, pH 7.4
0.043
menadione
pH 6.5, 25°C
0.045 - 0.06
menadione
-
Km depending on enzyme form
0.05 - 0.07
menadione
-
Km depending on enzyme form
0.055
menadione
-
mutant V88I, 37°C, pH 7.4
0.004 - 0.01
NADPH
-
+ 4-nitrobenzaldehyde, Km depending on enzyme form
0.085
NADPH
-
pH 7.4, 37°C, recombinant isozyme CBR M244
0.0905
NADPH
-
pH 7.4, 37°C, recombinant isozyme CBR V244
0.247
NADPH
-
wild-type, 37°C, pH 7.4
0.343
NADPH
-
mutant V88I, 37°C, pH 7.4
1
Phenylglyoxal
-
-
4 - 5
Phenylglyoxal
-
Km depending on enzyme form
0.1
prostaglandin E2
-
-
0.24
prostaglandin E2
-
form CR2
0.309
prostaglandin E2
-
wild-type, 37°C, pH 7.4
0.32
prostaglandin E2
-
mutant V88I, 37°C, pH 7.4
0.49 - 2
pyridine-4-carboxaldehyde
-
Km depending on enzyme form
1.4
pyridine-4-carboxaldehyde
-
-
0.832
S-nitrosoglutathione
mutant Q142M/C143S/P230W/D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244P/H270S, pH 7.4, temperature not specified in the publication
1.09
S-nitrosoglutathione
mutant P230W/D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244PpH 7.4, temperature not specified in the publication
2.93
S-nitrosoglutathione
mutant D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244P, pH 7.4, temperature not specified in the publication
additional information
additional information
recombinant enzyme, steady-state kinetics, molecular modeling and substrate docking studies
-
additional information
additional information
-
-
-
additional information
additional information
-
overview
-
additional information
additional information
-
the glucocorticoid and xenobiotic reductase activities show cooperative kinetics
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3.47 - 6.7
1,2-naphthoquinone
0.25 - 0.55
1,4-Naphthoquinone
0.32 - 5.13
2,3-Hexanedione
30.5
3-glutathionyl-hexanal
pH 8.4, 25°C
30.8
3-glutathionyl-nonanal
pH 8.4, 25°C
190.8
3-glutathionyl-propanal
pH 8.4, 25°C
1 - 2.02
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
0.25 - 1.2
4-benzoylpyridine
3.57 - 36.2
9,10-phenanthrenequinone
66.7
9,10-phenantrenequinone
at pH 8.4 and 37°C
-
0.0103 - 0.21
doxorubicin
30.8
glutathionyl-nonanal
at pH 8.4 and 37°C
-
2.02 - 2.62
S-nitrosoglutathione
6.75
3-glutathionyl-4-hydroxynonanal
-
pH 8.4, 37°C
0.009167 - 0.012
4-benzoylpyridine
0.0098
4-nitrobenzaldehyde
pH 6.5, 25°C
220
4-oxonon-2-enal
-
pH 7.4, 37°C, recombinant enzyme
8.6
glutathione-4-oxonon-2-enal
-
pH 7.4, 37°C, recombinant enzyme
5.05 - 20.45
S-nitrosoglutathione
3.47
1,2-naphthoquinone
wild-type, pH 7.4, 25°C
3.47
1,2-naphthoquinone
wild-type, pH 7.4, 37°C
6.7
1,2-naphthoquinone
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
6.7
1,2-naphthoquinone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.25
1,4-Naphthoquinone
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.28
1,4-Naphthoquinone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.55
1,4-Naphthoquinone
wild-type, pH 7.4, 25°C
0.55
1,4-Naphthoquinone
wild-type, pH 7.4, 37°C
0.32
2,3-Hexanedione
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
1.52
2,3-Hexanedione
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
5.13
2,3-Hexanedione
wild-type, pH 7.4, 25°C
5.13
2,3-Hexanedione
wild-type, pH 7.4, 37°C
1
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
2.02
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
wild-type, pH 7.4, 37°C
0.25
4-benzoylpyridine
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.3
4-benzoylpyridine
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
1.2
4-benzoylpyridine
wild-type, pH 7.4, 25°C
1.2
4-benzoylpyridine
wild-type, pH 7.4, 37°C
3.57
9,10-phenanthrenequinone
wild-type, pH 7.4, 25°C
3.57
9,10-phenanthrenequinone
wild-type, pH 7.4, 37°C
5.25
9,10-phenanthrenequinone
wild-type, pH 7.4, temperature not specified in the publication
6.7
9,10-phenanthrenequinone
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
9.77
9,10-phenanthrenequinone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
36.2
9,10-phenanthrenequinone
mutant C227S, pH 7.4, temperature not specified in the publication
0.48
daunorubicin
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
1.19
daunorubicin
single nucleotide polymorphism V88I mutation
1.27
daunorubicin
wild-type, pH 7.4, 37°C
1.94
daunorubicin
wild-type
2.02
daunorubicin
single nucleotide polymorphism P131S mutation
0.0103
doxorubicin
-
0.15
doxorubicin
single nucleotide polymorphism V88I mutation
0.18
doxorubicin
single nucleotide polymorphism P131S mutation
0.21
doxorubicin
wild-type
0.17
isatin
wild-type, pH 7.4, 25°C
0.17
isatin
wild-type, pH 7.4, 37°C
0.3
isatin
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
9.77
isatin
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.19
menadione
single nucleotide polymorphism V88I mutation
0.28
menadione
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
0.32
menadione
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.33
menadione
single nucleotide polymorphism P131S mutation
0.68
menadione
wild-type, pH 7.4, 25°C
0.68
menadione
wild-type, pH 7.4, 37°C
0.38
oracin
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
1.67
oracin
wild-type, pH 7.4, 37°C
2.02
S-nitrosoglutathione
mutant C227S, pH 7.4, temperature not specified in the publication
2.62
S-nitrosoglutathione
wild-type, pH 7.4, temperature not specified in the publication
0.009167
4-benzoylpyridine
-
mutant P230W
0.0103
4-benzoylpyridine
-
wild-type
0.012
4-benzoylpyridine
pH 6.5, 25°C
61
daunorubicin
-
mutant V88I, 37°C, pH 7.4
91
daunorubicin
-
wild-type, 37°C, pH 7.4
0.0092
menadione
pH 6.5, 25°C
0.011
menadione
-
wild-type
0.01217
menadione
-
mutant P230W
9.9
menadione
-
pH 7.4, 37°C, recombinant isozyme CBR V244
20.5
menadione
-
pH 7.4, 37°C, recombinant isozyme CBR M244
85
menadione
-
mutant V88I, 37°C, pH 7.4
110
menadione
-
wild-type, 37°C, pH 7.4
246
menadione
-
pH 7.4, 37°C, recombinant enzyme
16.3
NADPH
-
pH 7.4, 37°C, recombinant isozyme CBR V244
26.7
NADPH
-
pH 7.4, 37°C, recombinant isozyme CBR M244
149
NADPH
-
mutant V88I, 37°C, pH 7.4
179
NADPH
-
wild-type, 37°C, pH 7.4
18
prostaglandin E2
-
mutant V88I, 37°C, pH 7.4
25
prostaglandin E2
-
wild-type, 37°C, pH 7.4
5.05
S-nitrosoglutathione
mutant D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244P, pH 7.4, temperature not specified in the publication
10.83
S-nitrosoglutathione
mutant P230W/D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244PpH 7.4, temperature not specified in the publication
20.45
S-nitrosoglutathione
mutant Q142M/C143S/P230W/D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244P/H270S, pH 7.4, temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
50 - 56.7
1,2-naphthoquinone
8.7 - 73.3
1,4-Naphthoquinone
25 - 31.7
2,3-Hexanedione
1281
3-glutathionyl-hexanal
pH 8.4, 25°C
4615
3-glutathionyl-nonanal
pH 8.4, 25°C
885
3-glutathionyl-propanal
pH 8.4, 25°C
0.17 - 0.25
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
4.8 - 15.7
4-benzoylpyridine
113 - 2828
9,10-phenanthrenequinone
2.5 - 93.45
S-nitrosoglutathione
1.72 - 24.58
S-nitrosoglutathione
50
1,2-naphthoquinone
wild-type, pH 7.4, 25°C
50
1,2-naphthoquinone
wild-type, pH 7.4, 37°C
56.7
1,2-naphthoquinone
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
56.7
1,2-naphthoquinone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
8.7
1,4-Naphthoquinone
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
8.7
1,4-Naphthoquinone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
73.3
1,4-Naphthoquinone
wild-type, pH 7.4, 25°C
73.3
1,4-Naphthoquinone
wild-type, pH 7.4, 37°C
25
2,3-Hexanedione
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
25
2,3-Hexanedione
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
31.6
2,3-Hexanedione
wild-type, pH 7.4, 25°C
31.7
2,3-Hexanedione
wild-type, pH 7.4, 37°C
0.17
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
0.25
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
wild-type, pH 7.4, 37°C
4.8
4-benzoylpyridine
wild-type, pH 7.4, 25°C
4.8
4-benzoylpyridine
wild-type, pH 7.4, 37°C
15.7
4-benzoylpyridine
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
15.7
4-benzoylpyridine
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
113
9,10-phenanthrenequinone
wild-type, pH 7.4, 25°C
113
9,10-phenanthrenequinone
wild-type, pH 7.4, 37°C
148.3
9,10-phenanthrenequinone
wild-type, pH 7.4, temperature not specified in the publication
533
9,10-phenanthrenequinone
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
533
9,10-phenanthrenequinone
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
2828
9,10-phenanthrenequinone
mutant C227S, pH 7.4, temperature not specified in the publication
11.2
daunorubicin
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
18.3
daunorubicin
wild-type, pH 7.4, 37°C
18.3
isatin
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
18.3
isatin
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
21.7
isatin
wild-type, pH 7.4, 25°C
21.7
isatin
wild-type, pH 7.4, 37°C
21.7
menadione
after treatment with S-nitrosoglutathione, pH 7.4, 25°C
21.7
menadione
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
38.3
menadione
wild-type, pH 7.4, 25°C
38.3
menadione
wild-type, pH 7.4, 37°C
11.3
oracin
enzyme modified by S-nitrosoglutathione, pH 7.4, 37°C
12.2
oracin
wild-type, pH 7.4, 37°C
2.5
S-nitrosoglutathione
mutant C227S, pH 7.4, temperature not specified in the publication
93.45
S-nitrosoglutathione
wild-type, pH 7.4, temperature not specified in the publication
1.72
S-nitrosoglutathione
mutant D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244P, pH 7.4, temperature not specified in the publication
9.93
S-nitrosoglutathione
mutant P230W/D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244PpH 7.4, temperature not specified in the publication
24.58
S-nitrosoglutathione
mutant Q142M/C143S/P230W/D236A/K238P/D239K/S240A/I241T/R242K/T243S/V244P/H270S, pH 7.4, temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0042
(2E)-1-(2,4-dihydroxyphenyl)-3-(2',4',6-trihydroxy-5'-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]biphenyl-3-yl)prop-2-en-1-one
Homo sapiens
pH 7.4, 37°C
0.034 - 0.383
3',4',7-tris[O-(2-hydroxyethyl)]rutin
0.0036
3-(2-(2,4-dihydroxyphenyl)-1-[hydroxy(4-hydroxyphenyl)methyl]-2-oxoethyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
pH 7.4, 37°C
0.0061
3-[2,3-dihydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-4H-chromen-4-one
Homo sapiens
pH 7.4, 37°C
0.0011
3-[2-(2,4-dihydroxyphenyl)-1-(4-hydroxybenzyl)-2-oxoethyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
pH 7.4, 37°C
0.0013
4-amino-1-tert-butyl-3-(2-hydroxyphenyl)pyrazolo[3,4-d]pyrimidine
Homo sapiens
for menadione metabolism
0.037 - 0.219
7-monohydroxyethylrutoside
0.008
7-O-beta-D-glucopyranos2-ulosyl-quercetin
Homo sapiens
pH 7.4, 37°C
0.00165 - 0.043
quercetin
0.00182 - 0.0065
quercitrin
0.00021
14,16-dihydroxy-3,8-dimethyl-3,4,5,6,9,10-hexahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione
Homo sapiens
-
pH 6.9, temperature not specified in the publication
0.0127
Biochanin A
Homo sapiens
-
pH 6.9, temperature not specified in the publication
0.00067
chrysin
Homo sapiens
-
pH 6.9, temperature not specified in the publication
0.0215
naringenin
Homo sapiens
-
pH 6.9, temperature not specified in the publication
0.00327
radiciol
Homo sapiens
-
pH 6.9, temperature not specified in the publication
0.0004
triclosan
Homo sapiens
-
pH 6.9, temperature not specified in the publication
0.00378
wedelolactone
Homo sapiens
-
pH 6.9, temperature not specified in the publication
0.034
3',4',7-tris[O-(2-hydroxyethyl)]rutin
Homo sapiens
CBR1 I88 with ddoxorubicin as substrate
0.053
3',4',7-tris[O-(2-hydroxyethyl)]rutin
Homo sapiens
CBR1 V88 with doxorubicin as substrate
0.214
3',4',7-tris[O-(2-hydroxyethyl)]rutin
Homo sapiens
CBR1 I88 with daunorubicin as substrate
0.383
3',4',7-tris[O-(2-hydroxyethyl)]rutin
Homo sapiens
CBR1 V88 with daunorubicin as substrate
0.037
7-monohydroxyethylrutoside
Homo sapiens
CBR1 I88 with doxorubicin as substrate
0.059
7-monohydroxyethylrutoside
Homo sapiens
CBR1 V88 with doxorubicin as substrate
0.164
7-monohydroxyethylrutoside
Homo sapiens
CBR1 I88 with daunorubicin as substrate
0.219
7-monohydroxyethylrutoside
Homo sapiens
CBR1 V88 with daunorubicin as substrate
0.00165
quercetin
Homo sapiens
at pH 8.4 and 37°C
0.0062
quercetin
Homo sapiens
pH 7.4, 37°C
0.014
quercetin
Homo sapiens
CBR1 I88 with daunorubicin as substrate
0.019
quercetin
Homo sapiens
CBR1 I88 with doxorubicin as substrate
0.025
quercetin
Homo sapiens
CBR1 V88 with daunorubicin as substrate
0.043
quercetin
Homo sapiens
CBR1 V88 with doxorubicin as substrate
0.00182
quercitrin
Homo sapiens
at pH 8.4 and 37°C
0.0065
quercitrin
Homo sapiens
pH 7.4, 37°C
0.00074
rutin
Homo sapiens
at pH 8.4 and 37°C
0.0021
rutin
Homo sapiens
pH 7.4, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Wermuth, B.
Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase
J. Biol. Chem.
256
1206-1213
1981
Homo sapiens
brenda
Bohren, K.M.; von Wartburg, J.P.; Wermuth, B.
Inactivation of carbonyl reductase from human brain by phenylglyoxal and 2,3-butanedione: a comparison with aldehyde reductase and aldose reductase
Biochim. Biophys. Acta
916
185-192
1987
Homo sapiens
brenda
Bohren, K.M.; von Wartburg, J.P.; Wermuth, B.
Kinetics of carbonyl reductase from human brain
Biochem. J.
244
165-171
1987
Homo sapiens
brenda
Inazu, N.; Ruepp, B.; Wirth, H.; Wermuth, B.
Carbonyl reductase from human testis: purification and comparison with carbonyl reductase from human brain and rat testis
Biochim. Biophys. Acta
1116
50-56
1992
Homo sapiens
brenda
Bohren, K.M.; Wermuth, B.; Harrison, D.; Ringe, D.; Petsko, G.A.; Gabbay, K.H.
Expression, crystallization and preliminary crystallographic analysis of human carbonyl reductase
J. Mol. Biol.
244
659-664
1994
Homo sapiens
brenda
Forrest, G.L.; Gonzalez, B.
Carbonyl reductase
Chem. Biol. Interact.
129
21-40
2000
Cavia porcellus, Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Schieber, A.; Frank, R.W.; Ghisla, S.
Purification and properties of prostaglandin 9-ketoreductase from pig and human kidney. Identity with human carbonyl reductase
Eur. J. Biochem.
206
491-502
1992
Homo sapiens, Sus scrofa
brenda
Wermuth, B.; Platts, K.L.; Seidel, A.; Oesch, F.
Carbonyl reductase provides the enzymatic basis of quinone detoxication in man
Biochem. Pharmacol.
35
1277-1282
1986
Homo sapiens
brenda
Doorn, J.A.; Maser, E.; Blum, A.; Claffey, D.J.; Petersen, D.R.
Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal
Biochemistry
43
13106-13114
2004
Homo sapiens
brenda
Maser, E.
Neuroprotective role for carbonyl reductase?
Biochem. Biophys. Res. Commun.
340
1019-1022
2006
Drosophila melanogaster, Homo sapiens
brenda
Takenaka, K.; Ogawa, E.; Oyanagi, H.; Wada, H.; Tanaka, F.
Carbonyl reductase expression and its clinical significance in non-small-cell lung cancer
Cancer Epidemiol. Biomarkers Prev.
14
1972-1975
2005
Homo sapiens
brenda
Slupe, A.; Williams, B.; Larson, C.; Lee, L.M.; Primbs, T.; Bruesch, A.J.; Bjorklund, C.; Warner, D.L.; Peloquin, J.; Shadle, S.E.; Gambliel, H.A.; Cusack, B.J.; Olson, R.D.; Charlier, H.A.
Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase
Cardiovasc. Toxicol.
5
365-376
2005
Homo sapiens (P16152)
brenda
Lakhman, S.S.; Ghosh, D.; Blanco, J.G.
Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)
Drug Metab. Dispos.
33
254-257
2005
Homo sapiens
brenda
Maser, E.; Wsol, V.; Martin, H.J.
11beta-Hydroxysteroid dehydrogenase type 1: purification from human liver and characterization as carbonyl reductase of xenobiotics
Mol. Cell. Endocrinol.
248
34-37
2006
Homo sapiens
brenda
Carlquist, M.; Frejd, T.; Gorwa-Grauslund, M.F.
Flavonoids as inhibitors of human carbonyl reductase 1
Chem. Biol. Interact.
174
98-108
2008
Homo sapiens (P16152), Homo sapiens
brenda
Gonzalez-Covarrubias, V.; Ghosh, D.; Lakhman, S.S.; Pendyala, L.; Blanco, J.G.
A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity
Drug Metab. Dispos.
35
973-980
2007
Homo sapiens
brenda
Miura, T.; Nishinaka, T.; Terada, T.
Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1
Mol. Cell. Biochem.
315
113-121
2008
Homo sapiens (O75828), Homo sapiens
brenda
Miura, T.; Itoh, Y.; Takada, M.; Tsutsui, H.; Yukimura, T.; Nishinaka, T.; Terada, T.
Investigation of the role of the amino acid residue at position 230 for catalysis in monomeric carbonyl reductase 3
Chem. Biol. Interact.
178
211-214
2009
Cricetulus griseus, Homo sapiens, Rattus norvegicus (B2GV72)
brenda
El-Hawari, Y.; Favia, A.D.; Pilka, E.S.; Kisiela, M.; Oppermann, U.; Martin, H.J.; Maser, E.
Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis
Chem. Biol. Interact.
178
234-241
2009
Homo sapiens (O75828), Homo sapiens (P16152)
brenda
Kassner, N.; Huse, K.; Martin, H.J.; Goedtel-Armbrust, U.; Metzger, A.; Meineke, I.; Brockmoeller, J.; Klein, K.; Zanger, U.M.; Maser, E.; Wojnowski, L.
Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver
Drug Metab. Dispos.
36
2113-2120
2008
Homo sapiens (P16152), Homo sapiens
brenda
Bains, O.S.; Karkling, M.J.; Grigliatti, T.A.; Reid, R.E.; Riggs, K.W.
Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin
Drug Metab. Dispos.
37
1107-1114
2009
Homo sapiens (P16152), Homo sapiens
brenda
Gonzalez-Covarrubias, V.; Zhang, J.; Kalabus, J.L.; Relling, M.V.; Blanco, J.G.
Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors
Drug Metab. Dispos.
37
400-407
2009
Homo sapiens (P16152), Homo sapiens
brenda
Gonzalez-Covarrubias, V.; Kalabus, J.L.; Blanco, J.G.
Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER)
Pharm. Res.
25
1730-1734
2008
Homo sapiens (P16152), Homo sapiens
brenda
Zimmermann, T.; Niesen, F.; Pilka, E.; Knapp, S.; Oppermann, U.; Maier, M.
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone
Bioorg. Med. Chem.
17
530-536
2009
Homo sapiens
brenda
Staab, C.A.; Hartmanova, T.; El-Hawari, Y.; Ebert, B.; Kisiela, M.; Wsol, V.; Martin, H.J.; Maser, E.
Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3
Chem. Biol. Interact.
191
95-103
2011
Homo sapiens (O75828), Homo sapiens (P16152)
brenda
Hartmanova, T.; Tambor, V.; Len?o, J.; Staab-Weijnitz, C.A.; Maser, E.; Wsol, V.
S-nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity
Chem. Biol. Interact.
202
136-145
2013
Homo sapiens (P16152), Homo sapiens
brenda
Molnari, J.; Myers, A.
Carbonyl reduction of bupropion in human liver
Xenobiotica
42
550-561
2012
Homo sapiens
brenda
Moschini, R.; Peroni, E.; Rotondo, R.; Renzone, G.; Melck, D.; Cappiello, M.; Srebot, M.; Napolitano, E.; Motta, A.; Scaloni, A.; Mura, U.; Del-Corso, A.
NADP(+)-dependent dehydrogenase activity of carbonyl reductase on glutathionylhydroxynonanal as a new pathway for hydroxynonenal detoxification
Free Radic. Biol. Med.
83
66-76
2015
Homo sapiens
brenda
Rotondo, R.; Moschini, R.; Renzone, G.; Tuccinardi, T.; Balestri, F.; Cappiello, M.; Scaloni, A.; Mura, U.; Del-Corso, A.
Human carbonyl reductase 1 as efficient catalyst for the reduction of glutathionylated aldehydes derived from lipid peroxidation
Free Radic. Biol. Med.
99
323-332
2016
Homo sapiens (P16152), Homo sapiens
brenda
Liang, Q.; Liu, R.; Du, S.; Ding, Y.
Structural insights on the catalytic site protection of human carbonyl reductase 1 by glutathione
J. Struct. Biol.
192
138-144
2015
Homo sapiens (P16152), Homo sapiens
brenda
Barracco, V.; Moschini, R.; Renzone, G.; Cappiello, M.; Balestri, F.; Scaloni, A.; Mura, U.; Del-Corso, A.
Dehydrogenase/reductase activity of human carbonyl reductase 1 with NADP(H) acting as a prosthetic group
Biochem. Biophys. Res. Commun.
522
259-263
2020
Homo sapiens (P16152), Homo sapiens
brenda
Moschini, R.; Rotondo, R.; Renzone, G.; Balestri, F.; Cappiello, M.; Scaloni, A.; Mura, U.; Del-Corso, A.
Kinetic features of carbonyl reductase 1 acting on glutathionylated aldehydes
Chem. Biol. Interact.
276
127-132
2017
Homo sapiens (P16152), Homo sapiens
brenda
Ramsden, D.; Smith, D.; Arenas, R.; Frederick, K.; Cerny, M.A.
Identification and characterization of a selective human carbonyl reductase 1 substrate
Drug Metab. Dispos.
46
1434-1440
2018
Homo sapiens (P16152), Homo sapiens
brenda
Morgan, R.A.; Beck, K.R.; Nixon, M.; Homer, N.Z.M.; Crawford, A.A.; Melchers, D.; Houtman, R.; Meijer, O.C.; Stomby, A.; Anderson, A.J.; Upreti, R.; Stimson, R.H.; Olsson, T.; Michoel, T.; Cohain, A.; Ruusalepp, A.; Schadt, E.E.; Bjoerkegren, J.L.M.; Andrew, R.; Kenyon, C.J.; Hadoke, P.W.F.; Odermatt, A.; Keen, J.
Carbonyl reductase 1 catalyzes 20beta-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity
Sci. Rep.
7
10633
2017
Equus caballus, Homo sapiens (P16152), Homo sapiens, Mus musculus (P48758)
brenda
Kandeel, M.; Al-Taher, A.; Al-Nazawi, M.; Ohhashi, K.
Substructural dynamics of the phase-I drug metabolizing enzyme, carbonyl reductase 1, in response to various substrate and inhibitor configurations
Trop. J. Pharm. Res.
18
1635-1641
2019
Homo sapiens (P16152)
-
brenda